1. Home
  2. BFAC vs RPTX Comparison

BFAC vs RPTX Comparison

Compare BFAC & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BFAC
  • RPTX
  • Stock Information
  • Founded
  • BFAC 2021
  • RPTX 2016
  • Country
  • BFAC United States
  • RPTX Canada
  • Employees
  • BFAC N/A
  • RPTX N/A
  • Industry
  • BFAC Blank Checks
  • RPTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BFAC Finance
  • RPTX Health Care
  • Exchange
  • BFAC Nasdaq
  • RPTX Nasdaq
  • Market Cap
  • BFAC 152.7M
  • RPTX 141.1M
  • IPO Year
  • BFAC 2021
  • RPTX 2020
  • Fundamental
  • Price
  • BFAC $11.14
  • RPTX $1.39
  • Analyst Decision
  • BFAC
  • RPTX Strong Buy
  • Analyst Count
  • BFAC 0
  • RPTX 3
  • Target Price
  • BFAC N/A
  • RPTX $7.00
  • AVG Volume (30 Days)
  • BFAC 4.3K
  • RPTX 569.3K
  • Earning Date
  • BFAC 01-01-0001
  • RPTX 11-07-2024
  • Dividend Yield
  • BFAC N/A
  • RPTX N/A
  • EPS Growth
  • BFAC 49.83
  • RPTX N/A
  • EPS
  • BFAC 0.37
  • RPTX N/A
  • Revenue
  • BFAC N/A
  • RPTX $66,524,000.00
  • Revenue This Year
  • BFAC N/A
  • RPTX $13.22
  • Revenue Next Year
  • BFAC N/A
  • RPTX N/A
  • P/E Ratio
  • BFAC $29.86
  • RPTX N/A
  • Revenue Growth
  • BFAC N/A
  • RPTX 18.19
  • 52 Week Low
  • BFAC $10.84
  • RPTX $1.47
  • 52 Week High
  • BFAC $11.55
  • RPTX $8.49
  • Technical
  • Relative Strength Index (RSI)
  • BFAC 67.74
  • RPTX 30.09
  • Support Level
  • BFAC $11.11
  • RPTX $2.97
  • Resistance Level
  • BFAC $11.14
  • RPTX $4.07
  • Average True Range (ATR)
  • BFAC 0.00
  • RPTX 0.33
  • MACD
  • BFAC 0.00
  • RPTX -0.19
  • Stochastic Oscillator
  • BFAC 100.00
  • RPTX 0.56

About BFAC Battery Future Acquisition Corp.

Battery Future Acquisition Corp is a blank check company.

About RPTX Repare Therapeutics Inc.

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.

Share on Social Networks: